Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Allergan Sales, LLC
EIR
•Allergan Sales, LLC•February 27, 2019

Allergan Sales, LLC – FDA EIR, Feb 27, 2019

Record Details

An FDA inspection of Allergan Sales, LLC's Waco, TX facility, a manufacturer of sterile ophthalmic drug products, was conducted from January 29 to February 27, 2019. This follow-up inspection assessed corrections made since a 2016 inspection which had resulted in an FDA-483 and an Untitled Letter; the previous deficiencies were found to be corrected. However, the current inspection revealed three new observations documented on an FDA-483. The main issues included a failure to adequately evaluate interventions during smoke studies for Multi Dose Line (b)(4), impacting procedures to prevent microbiological contamination (21 CFR 211.113(b)). There was also a deficiency in environmental monitoring, as a risk assessment did not evaluate a specific component within the Grade A area of Multi Dose Line (b)(4) (21 CFR 211.42(c)(10)(iv)). Lastly, cleaning and disinfecting procedures for aseptic areas were incomplete, specifically lacking a reference to certain wipes used for cleaning in the Grade A area of Multi Dose Line (b)(4) (21 CFR 211.42(c)(10)(v)). Allergan's management committed to submitting a written response within 15 business days. For the cleaning procedure observation, an updated SOP was provided during the inspection to incorporate the missing details.

Company
Allergan Sales, LLC
Inspection date
February 27, 2019
Product type
drugs
Office
Dallas District Office
People
  • Stephen D. Brown (Principal Consultant)
  • Justin Kuykendall (company_representative)
  • Manuel Torrado (company_representative)
  • Tom Treacy (company_representative)
  • Kyle Green (company_representative)
View Company Profile

ID · 093578ba-d845-4cf3-9593-cb92ccc6efe2

Violation Codes5
21 CFR 211.113(b)21 CFR 211.42(c)(10)(iv)21 CFR 820.19821 CFR 211.42(c)(10)(v)21 CFR 820.50

Full citation text and observation details available on the Dashboard.

Other documents for Allergan Sales, LLC
  • 483 - 2026-07-31July 31, 2026
  • EIR - 2019-06-06June 6, 2019
  • 483 - 2019-02-27February 27, 2019
  • 483 - 2016-10-28October 28, 2016
  • EIR - 2016-10-28October 28, 2016

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Allergan Sales, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.